Related Experiment Video
Updated: Jun 5, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor
Mariano A Giorgi1, Hernán Cohen Arazi, Claudio D Gonzalez
1Department of Cardiology and Cardiovascular Surgery, Instituto FLENI, Montañes, Buenos Aires, Argentina. marianoagiorgi@hotmail.com
Expert Opinion on Pharmacotherapy
|January 25, 2011
Summary
Clopidogrel response varies due to complex pharmacokinetics. Prasugrel and ticagrelor offer faster, greater antiplatelet effects, aiding personalized patient management.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Drug Metabolism
Background:
- Variability in clinical response to clopidogrel is linked to individual patient factors.
- This variability has driven the development of alternative P2Y12 receptor inhibitors like prasugrel and ticagrelor.
Purpose of the Study:
- To compare the pharmacokinetic and pharmacodynamic profiles of clopidogrel, prasugrel, and ticagrelor.
- To explain how drug kinetics influence clinical efficacy and safety.
- To guide the selection of P2Y12 inhibitors for optimal patient outcomes.
Main Methods:
- Review of pharmacokinetic characteristics of clopidogrel, prasugrel, and ticagrelor.
- Analysis of factors influencing clopidogrel metabolism, including genetic polymorphisms and drug-drug interactions.
- Comparison of the onset, extent, and duration of antiplatelet effects.
Main Results:
- Clopidogrel exhibits complex pharmacokinetics, making it susceptible to genetic variations and drug interactions.
- Prasugrel and ticagrelor possess simpler metabolic pathways, leading to greater bioavailability and reduced susceptibility to interactions.
- Both prasugrel and ticagrelor achieve a faster and more potent antiplatelet effect compared to clopidogrel.
Conclusions:
- While clopidogrel remains a standard, its pharmacokinetic variability poses challenges.
- Prasugrel and ticagrelor offer pharmacokinetic advantages, enabling more tailored antiplatelet therapy.
- Personalized patient management through appropriate drug selection is crucial for optimizing treatment with P2Y12 inhibitors.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:20Measurement of Bioavailability: Pharmacodynamic Methods
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.